ProQuad

Vaccination against MMR & varicella in individuals 12 mth-12 yr.

SC Childn 12 mth-12 yr Single dose. At least 1 mth should elapse between a dose of M-M-R II & a dose of ProQuad. Min of 3-mth dose interval, if a 2nd dose of varicella-containing vaccine is administered.

Hypersensitivity to MMR & varicella including gelatin. History of anaphylactoid reaction to neomycin. Blood dyscrasias, leukemia, lymphomas of any type or other malignant neoplasms affecting the bone marrow or lymphatic system. Immunosuppressive therapy (including high-dose corticosteroids). Primary & acquired immunodeficiency states including immunosuppression in association w/ AIDS or other clinical manifestations of infection w/ HIV; cellular immune deficiencies; & hypogammaglobulinemic & dysgammaglobulinemic states. Family history of congenital or hereditary immunodeficiency. Active untreated TB. Any active febrile illness w/ fever >38.5°C. Pregnancy.

Hypersensitivity to eggs (low risk for anaphylactic reactions in childn). Adequate treatment provisions including epinephrine inj should be available for immediate use if anaphylactic or anaphylactoid reaction occur. Do not inj intravascularly. Obtain vaccination history & determine previous reactions to any vaccine prior to administration. History of convulsions, cerebral injury or any other condition in which stress due to fever should be avoided. HIV w/ or w/o evidence of immunosuppression. May not protect all vaccine recipients. Avoid close association w/ high-risk individuals (immunocompromised, pregnant women w/o documented +ve history of varicella or lab evidence of prior infection & their newborns) susceptible to varicella for up to 6 wk following vaccination. Individuals w/ thrombocytopenia. Post-exposure prophylaxis. May result in temporary depression of tuberculin skin sensitivity; administer tuberculin test any time before, simultaneously w/ or at least 4-6 wk after ProQuad. Concomitant vaccination w/ diphtheria, tetanus & acellular pertussis. Not to be given concomitantly w/ Ig or varicella-zoster Ig. Avoid pregnancy 3 mth following vaccination. Lactation. Not recommended for infant <12 mth. Childn w/ untreated TB. Adolescents & adults. Not indicated for elderly >65 yr.

Fever ≥38.9°C, erythema or pain/tenderness/soreness at the inj site. Upper resp infection; irritability; diarrhea, vomiting; rash, measles-like & varicella-like rash; ecchymosis or swelling at inj site, inj site rash.

May interfere w/ the expected immune response w/ Ig. Defer vaccination at least 3 mth following blood/plasma transfusion or Ig administration. Risk of Reye syndrome w/ salicylates (avoid use for 6 wk after vaccination). Concomitant use w/ inactivated poliovirus, pneumococcal conjugate & meningococcal C conjugate vaccines.

Vaccines, Antisera & Immunologicals

J07BD54 - measles, combinations with mumps, rubella and varicella, live attenuated ; Belongs to the class of measles vaccines.

POM